article Open AccessTop 1% cited

BSR and BHPR guidelines for the management of giant cell arteritis

Lara D. Veeken · 2010 · Vol. 49(8) · pp. 1594–1597

Bhaskar Dasgupta✉(University of London)Frances Borg(University of London)N. Hassan(University of London)Leo Daniel Alexander(University of London)Kevin Barraclough(University of London)Brian P. Bourke(University of London)J. Fulcher(University of London)J Hollywood(University of London)Andrew Hutchings(University of London)Philip James(University of London)V Kyle(University of London)J C Nott(University of London)Michael Power(University of London)A. Samanta(University of London)on behalf of the BSR and BHPR Standards, Guidelines and Audit Working Group

View via DOI Full-text PDF

Abstract

Scope and purpose GCA is the commonest of all the vasculitides. Visual loss occurs in up to one-fifth of patients, which may be preventable by prompt recognition and treatment [1,2]. The aim of these guidelines is to encourage the prompt diagnosis and management of GCA, with emphasis on the prevention of visual loss. Their scope is to provide evidence-based advice for the assessment and diagnosis of GCA, for initial and further management and for monitoring of disease activity, complications and relapse. This is a summary of the guidelines and the full guideline is available at Rheumatology online.

Vasculitis and related conditions Otitis Media and Relapsing Polychondritis Coagulation, Bradykinin, Polyphosphates, and AngioedemaMedicineGiant cell arteritisArteritisTakayasu arteritisDermatologyVasculitisInternal medicineDisease

MeSH terms

AdolescentAdultAgedAlgorithmsChildChild, PreschoolGlucocorticoidsUnited KingdomHumansInfantMiddle AgedGiant Cell ArteritisPractice Guidelines as TopicYoung Adult

Citations

443

FWCI

17.08

field-weighted impact

References

Percentile

99%

vs. same field & year

Citations per year

Cited by

Cardiovascular toxicities associated with immune checkpoint inhibitors